Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain
← catalyst calendarNCT06827262 · readout ≤ 2,903 d
Sponsored by Boston Scientific Corporation (industry) · BSX — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
1,500estimated
Sites
19
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-26 | actual | When the study began enrolling |
| Primary completion | Jul 2034 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2034 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Chronic Low-back Pain
- Vertebrogenic Pain Syndrome
Intervention
- Device: Intracept™ Intraosseous Nerve Ablation
Primary outcome
what the primary-completion date above is the date OFChange in Disability (Oswestry Disability Index (ODI) from Baseline
measured 60-months post-procedure
Permalink · BSX's whole pipeline · Catalyst calendar · Every registered study · What changed